All stock reports

BALPHARMA evidence report

Evidence date: 2026-10-01. Research observations only.

What can I do with this stock?

Evaluated 2026-10-02T01:37:53.224812+00:00. Closed-session evidence: 2026-10-01. This is a timestamped assessment, not a live trading feed.

Strategy evidence, instrument feasibility and portfolio suitability are separate. Portfolio suitability has not been assessed.

Today: intraday

Evidence unavailable

No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

  • No current intraday signal and observed quote supplied; daily bars cannot establish a live setup.

Next week: five trading sessions

No qualifying opportunity

No candidate with a primary five-session horizon in the coherent source run.

  • No candidate with a primary five-session horizon in the coherent source run.

Long term: one to three years

Research only

A financial screen alone does not establish an investment recommendation.

  • A current, source-backed thesis and valuation review is required.

Investment evidence

Statement coverage
FULL_STATEMENTS
Financial source retrieved
2026-08-28T23:40:45.272108+00:00

Metrics

latest_annual_period
2026-03-31
revenue
3116613000.0
net_income
62835000.0
operating_cash_flow
144720000.0
free_cash_flow
-40829000.0
total_assets
3755399000.0
total_liabilities
2932875000.0
total_equity
822274000.0
cash
92917000.0
total_debt
1595164000.0
revenue_growth
0.028302450184487293
earnings_growth
-0.1291543088394268
net_margin
0.020161309729504435
roe
0.07641613379481779
debt_to_equity
1.9399421603990883
cash_conversion
2.3031749820959657
free_cash_flow_margin
-0.013100439483503406
trailing_pe
23.0127
forward_pe
0.0
peg_ratio
Not supplied
price_to_book
1.7277
dividend_yield
0.0134

Other positional research

No qualifying opportunity

No candidate at another positional horizon in the coherent source run.

  • No candidate at another positional horizon in the coherent source run.
Decision provenance and limitations
Decision ID
decision-b56c0cfa322a2c51a00e50e6338b768d07875b3d3a59c4d26b9599a0c69d3c3f
Policy
stock-decisions-v1
Evidence bundle hash
e5cdc17c793df5efb54477a7991fa902f99d4e895a3557c64540c7dc56c5cbdd
  • market-brief: a7de4d64fedac164d48cdfb9b4081a4666d7f797f7d9c58da304b329b3a61d3c
  • validation-registry: b1069587129bfc64a703cdf8322d0294692585b7d67f5472593e4164bbb0c3bc
  • financial-statements: 50eb617667e97c6e947adbd10b618a3627d2eed213d83164bbe01e8daf0e8ff6
  • daily-price: 09bb14ab9a28097fc2b62a47a36097ec2e02b2d32a710b6552e696855a27f300
  • Conditional research decisions are not orders or personalized position sizes.
  • Scenario payoffs are assumptions, not probabilities or expected returns.
  • A stop price does not guarantee a maximum loss through a gap or illiquidity.

Download the decision evidence as JSON

Evidence briefing

The local language model selected and grouped the following supplied facts.

Overview

Price source verification: REPAIRED. The trailing 20-session price return was 24.94%. The trailing 60-session price return was 38.68%. The cached financial metric revenue growth is 0.028302450184487293.

Risks

The closing price was -6.50% below its highest close in the available trailing year. The cached financial metric debt to equity is 1.9399421603990883. The cached financial metric free cash flow margin is -0.013100439483503406. Historical observations do not establish future returns. No verified current news or catalyst evidence is supplied.

Follow Up

Average cached traded value over twenty sessions was INR 16,848,798. The cached financial metric roe is 0.07641613379481779. The cached financial metric net margin is 0.020161309729504435. The cached financial metric cash conversion is 2.3031749820959657.

Cached observations and evidence limits